These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38108390)

  • 1. Immunohistochemical Expression of Immune Checkpoints; CTLA-4, LAG3, and TIM-3 in Cancer Cells and Tumor-infiltrating Lymphocytes (TILs) in Colorectal Carcinoma.
    Abdelrahman DI; Elhasadi I; Anbaig A; Bakry A; Mandour D; Wasefy T; Yehia AM; Alorini M; Shalaby AM; Yahia AIO; Alabiad MA
    Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):71-83. PubMed ID: 38108390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
    Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
    World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role and relationship between programmed death ligand 1 and cytotoxic T lymphocyte-associated antigen-4 immunohistochemical expression in colorectal carcinoma patients: an impact on outcome.
    El Dein Mohameda AS; El-Rebey HS; AboElnasr LSA; Abdou AG
    Ecancermedicalscience; 2021; 15():1323. PubMed ID: 35047074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes.
    Kamal AM; Wasfey EF; Elghamry WR; Sabry OM; Elghobary HA; Radwan SM
    Clin Biochem; 2021 Oct; 96():13-18. PubMed ID: 34217699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer.
    Cabioglu N; Onder S; Oner G; Karatay H; Tukenmez M; Muslumanoglu M; İgci A; Eralp Y; Aydiner A; Saip P; Yavuz E; Ozmen V
    BMC Cancer; 2021 Apr; 21(1):357. PubMed ID: 33823818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Co-inhibitory Receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in Medullary Thyroid Cancers: A Large Cohort Study.
    Shi X; Li CW; Tan LC; Wen SS; Liao T; Zhang Y; Chen TZ; Ma B; Yu PC; Lu ZW; Qu N; Wang Y; Shi RL; Wang YL; Ji QH; Wei WJ
    J Clin Endocrinol Metab; 2021 Jan; 106(1):120-132. PubMed ID: 33000173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoints in Circulating and Tumor-Infiltrating CD4
    Toor SM; Murshed K; Al-Dhaheri M; Khawar M; Abu Nada M; Elkord E
    Front Immunol; 2019; 10():2936. PubMed ID: 31921188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of Tim3
    Klapholz M; Drage MG; Srivastava A; Anderson AC
    J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint proteins (PD-L1 and CTLA-4) in endometrial carcinoma: prognostic role and correlation with CD4
    Khalifa R; Elsese N; El-Desouky K; Shaair H; Helal D
    J Immunoassay Immunochem; 2022 Mar; 43(2):192-212. PubMed ID: 34697997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocyte-activated gene-3 (LAG3) protein expressed in tumor-infiltrating lymphocytes of colorectal cancer.
    Xu J; Shen D; Zhang T; Wang J; De W; Zhang J
    Pol J Pathol; 2021; 72(4):324-330. PubMed ID: 35308003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
    Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
    Front Immunol; 2021; 12():705378. PubMed ID: 34526987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relationship Between Tim-3 and Galectin-9 Expression Levels, Clinical Pathological Characteristics, and Prognosis in Patients After Radical Resection of Colorectal Cancer].
    Zhang Y; Deng D; Yin W; Luo J; Liu J; Xie C; Ji X; Ma L; Zhang L; Xia X; Cheng S; Huang A; Yang F
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2024 Mar; 55(2):375-382. PubMed ID: 38645842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Implications of Immune Infiltrates in the Breast Cancer Microenvironment: The Role of Expressions of CTLA-4, PD-1, and LAG-3.
    Bagbudar S; Karanlik H; Cabioglu N; Bayram A; Ibis K; Aydin E; Yavuz E; Onder S
    Appl Immunohistochem Mol Morphol; 2022 Feb; 30(2):99-107. PubMed ID: 34608875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts.
    Wuerdemann N; Pütz K; Eckel H; Jain R; Wittekindt C; Huebbers CU; Sharma SJ; Langer C; Gattenlöhner S; Büttner R; Speel EJ; Suchan M; Wagner S; Quaas A; Klussmann JP
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-Cell Immunoglobulin Mucin 3 Expression on Tumor Infiltrating Lymphocytes as a Positive Prognosticator in Triple-Negative Breast Cancer.
    Byun KD; Hwang HJ; Park KJ; Kim MC; Cho SH; Ju MH; Lee JH; Jeong JS
    J Breast Cancer; 2018 Dec; 21(4):406-414. PubMed ID: 30607162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological features and prognostic analysis of 247 small cell lung cancer with limited-stage after surgery.
    Liu L; Wei J; Teng F; Zhu Y; Xing P; Zhang J; Guo Y; Dong J; Ying J; Li J; Yang L
    Hum Pathol; 2021 Feb; 108():84-92. PubMed ID: 33245986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Distribution of TIM-3
    Zhuang C; Ni B; Zhang ZZ; Zhao WY; Tu L; Ma XL; Yang LX; Cao H; Wang M
    J Immunol Res; 2021; 2021():6647292. PubMed ID: 33681387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating and Tumor-Infiltrating Immune Checkpoint-Expressing CD8
    Alsalman A; Al-Mterin MA; Murshed K; Alloush F; Al-Shouli ST; Toor SM; Elkord E
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8
    Meyiah A; Mahmoodi Chalbatani G; Al-Mterin MA; Malekraeisi MA; Murshed K; Elkord E
    Int Immunopharmacol; 2023 Jun; 119():110207. PubMed ID: 37099940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
    Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
    Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.